Company intelligence / Profile preview

Harris FRC

Holmdel, New Jersey, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Harris FRC was a single-asset, family-held biotech company that owned the key patent rights to lacosamide (marketed as VIMPAT), an anti-seizure drug commercialized by UCB. The company’s only notable business was collecting licensing revenue from this intellectual property. These rights were sold in July 2020 for $342 million, after which the entity became non-operational and exists as a holding vehicle for cash and legal disputes.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Schwarz PharmaUCB

Beyond the preview

Go deeper on Harris FRC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harris FRC.

Explore the full profile